Kerala Ayurveda Ltd (530163)
🎯 Key Takeaways
- Kerala Ayurveda Ltd is in a distressed phase marked by persistent losses, negative cash flows, and deteriorating profitability, with ROE and ROCE severely negative. The company has swung from a modest profit in June 2025 to consecutive quarterly losses, signaling operational and financial strain.
- Revenue declined 4.5% QoQ to ₹33 in Q1FY27.
- ⚠️ Persistent quarterly losses with no clear path to profitability.
📖 The Story
Kerala Ayurveda Ltd is in a distressed phase marked by persistent losses, negative cash flows, and deteriorating profitability, with ROE and ROCE severely negative. The company has swung from a modest profit in June 2025 to consecutive quarterly losses, signaling operational and financial strain. Despite stable promoter holding, investor confidence appears low given the scale of losses and weak market returns.
📰 What's Happening
Management has not announced any strategic restructuring or new growth initiatives in the latest filings. The company continues to operate at a loss, with operating margins worsening from -8.1% in December 2025 to -25.3% in March 2026. There has been no material M&A, capital raise, or expansion disclosed recently. The consistent decline in profitability and rising borrowings suggest ongoing financial pressure without visible corrective actions.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 29 | 35 | 33 | 35 | 33 |
| Operating Profit | -6 | -6 | -3 | -9 | -6 |
| OPM % | -20.4% | -17.1% | -8.1% | -25.3% | -17.2% |
| Net Profit | 2 | -6 | -5 | -7 | -8 |
| EPS | ₹1.92 | ₹-7.23 | ₹-3.81 | ₹-5.83 | ₹-6.24 |
Revenue has remained relatively flat around ₹33–35 crore over the past year, but profitability has sharply declined, turning from a ₹2 crore profit in June 2025 to ₹8 crore loss in June 2026. Operating margins have deteriorated from -20.4% to -17.2%, with a notable acceleration in losses in Q1FY27. The company has not yet demonstrated cost control or margin recovery, and the lack of revenue growth amid rising financial charges raises concerns about operational efficiency.
🔮 Management Outlook & What's Next
There is no forward guidance or strategic outlook provided in the latest regulatory filings. Management has not addressed the profitability crisis, cash flow issues, or path to breakeven in any disclosed commentary. The absence of any commentary on future performance or corrective measures suggests a lack of clear direction or confidence in near-term improvement.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 13 |
| Reserves | 24 | -3 | -7 | -2 |
| Borrowings | 64 | 66 | 85 | 86 |
| Total Liabilities | 139 | 129 | 135 | 138 |
| Fixed Assets | 25 | 47 | 32 | 33 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 139 | 129 | 135 | 138 |
The balance sheet shows a sharp rise in borrowings from ₹66 crore in March 2025 to ₹86 crore in March 2026, while equity remains nearly stagnant at ₹12–13 crore. Reserves have turned increasingly negative, indicating accumulated losses are eroding capital. This pattern reflects aggressive borrowing to fund operations without meaningful equity growth, raising solvency concerns if profitability does not improve.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +5 |
| Investing | -15 |
| Financing | -9 |
| Net Cash Flow | -19 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 33.1% | 33.1% | 35.6% | 35.6% |
| FII | 0.0% | 0.2% | 0.2% | 0.2% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 44.4% | 44.4% | 42.2% | 42.0% |
| # Shareholders | 9,938 | 9,952 | 10,225 | 10,372 |
Promoter holding has remained stable at 35.61% over the last two quarters, but institutional interest is negligible — FII and DII holdings are below 0.2% and have shown no accumulation. The number of public shareholders has slightly increased, but this may reflect retail trading activity rather than confidence. The lack of institutional inflows amid deteriorating fundamentals suggests limited investor conviction.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.69 L Cr | 38.8 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.45 L Cr | 83.9 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.89 L Cr | 79.4 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.14 L Cr | 33.9 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.03 L Cr | 94.1 | 20.8% | 20.6% | 0.45 |
| LUPIN | 99,585 | 17.6 | 27.9% | 24.7% | 0.26 |
| MANKIND | 99,078 | 48.5 | 13.9% | 12.7% | 0.38 |
| DRREDDY | 97,240 | 30.1 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 97,239 | 26.4 | 12.8% | 9.8% | 0.20 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Persistent quarterly losses with no clear path to profitability. 2. Rapid increase in debt to fund operations, with no asset growth to show for it. 3. Negative equity reserves and deteriorating balance sheet strength. 4. Absence of management commentary or strategic response to worsening financials.
🧠 Analyst's Read
The company is facing a critical inflection point with no visible corrective strategy. Investors should monitor for any shift in management stance, debt restructuring, or signs of margin stabilization. Until then, the risk of further capital erosion remains high.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd